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USP45 deubiquitylase controls ERCC1–XPF
endonuclease-mediated DNA damage responses
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Abstract
Reversible protein ubiquitylation plays important roles in various
processes including DNA repair. Here, we identify the deubiquity-
lase USP45 as a critical DNA repair regulator. USP45 associates
with ERCC1, a subunit of the DNA repair endonuclease XPF–ERCC1,
via a short acidic motif outside of the USP45 catalytic domain.
Wild-type USP45, but not a USP45 mutant defective in ERCC1 bind-
ing, efficiently deubiquitylates ERCC1 in vitro, and the levels of
ubiquitylated ERCC1 are markedly enhanced in USP45 knockout
cells. Cells lacking USP45 are hypersensitive specifically to UV irra-
diation and DNA interstrand cross-links, similar to cells lacking
ERCC1. Furthermore, the repair of UV-induced DNA damage is
markedly reduced in USP45-deficient cells. ERCC1 translocation to
DNA damage-induced subnuclear foci is markedly impaired in
USP45 knockout cells, possibly accounting for defective DNA repair.
Finally, USP45 localises to sites of DNA damage in a manner depen-
dent on its deubiquitylase activity, but independent of its ability to
bind ERCC1–XPF. Together, these results establish USP45 as a new
regulator of XPF–ERCC1 crucial for efficient DNA repair.
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Introduction
Protein ubiquitylation is a post-translational modification that
plays a critical role in regulating biological processes (Hershko &
Ciechanover, 1998; Kerscher et al, 2006). The first step of the
ubiquitylation process involves the covalent attachment via an
isopeptide linkage of the C-terminal carboxyl residue of ubiquitin
to the epsilon amine group of a Lys residue side chain on the
target protein. Extra ubiquitin moieties can then be conjugated to
any one of the ubiquitin Lys residues (Lys6, Lys11, Lys27, Lys29,
Lys33, Lys48 and Lys63) or the amino terminal Met1 residue to form
polyubiquitin chains (Komander & Rape, 2012). The most extensively
studied role for ubiquitylation is Lys48-linked targeting of proteins
for 26S proteasome-mediated degradation (Glickman & Maytal,
2002). More recent work has revealed crucial roles for other types of
ubiquitylation including monoubiquitylation and other types of
polyubiquitin chain, in particular the K63 and K11 linkages (Ikeda &
Dikic, 2008). Hybrid polyubiquitin chains made up of diverse
ubiquitin linkages have also been detected in cells (Guzzo et al,
2012; Emmerich et al, 2013). The diverse polyubiquitin chains
regulate cell functions such as gene transcription, DNA repair and
replication, immune cell signalling, intracellular trafficking and many
more (Hershko & Ciechanover, 1998; Kulathu & Komander, 2012).
Key features of ubiquitylation that are likely to account for why it
has been selected as a major regulatory mechanism is that it is
inducible, reversible and can serve as a scaffolding mechanism to
recruit diverse sets of proteins that recognise mono- and specific
polyubiquitin chains. The enzymes that assemble and disassemble
ubiquitin chains underpin the versatility of the ubiquitin system.
Three types of ubiquitin enzymes (E1, E2 and E3) control the conjuga-
tion of ubiquitin to targets (Pickart, 2001) and approaching 100 deubi-
quitylases (DUBs) act to reverse ubiquitylation (Nijman et al, 2005).
The catalytic domains of DUBs have been subdivided into five
families based on the nature of their catalytic domains, namely
ubiquitin-specific proteases (USPs), ubiquitin C-terminal hydrolases
(UCHs), Machado–Joseph disease protein domain proteases (MJDs),
ovarian tumour proteases (OTUs), monocyte chemotactic protein-
induced protein proteases (MCPIP) and JAB/MPN/Mov34 metal-
loenzyme proteases (JAMM) (Nijman et al, 2005; Komander et al,
2009). JAMM DUBs are metalloproteases, whereas the rest of the
families are cysteine proteases (Nijman et al, 2005; Komander et al,
2009). Although several OTU members display marked selectivity
towards certain ubiquitin chain linkages, the majority of DUBs,
especially those belonging to the USP group, display no significant
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intrinsic selectivity towards ubiquitin chain topologies (Rago et al,
2007; Faesen et al, 2011; Ritorto et al, 2014).
We were interested in studying the role of ubiquitin-specific-
processing protease 45 (USP45), as cancer genome analysis has
revealed that ~12% of prostate cancers and ~5% of diffuse large
B-cell lymphoma display deletions in the USP45 gene (http://
www.cbioportal.org). USP45 is also one of the least well-
characterised DUBs and is highly conserved with clear homologues
in mammals, fish, frog, fly (Drosophila CG4165) and worm (Caenor-
habditis elegans CYK-3). USP45 belongs to a group of twelve related
USP isoforms (USP3, USP5, USP13, USP16, USP20, USP22, USP33,
USP39, USP44, USP49 and USP51) that possess a short N-terminal
region specific to each isoform bearing no obvious functional motif
(residues 1–61 USP45), followed by an N-terminal zinc finger–
ubiquitin-binding protein (Znf-UBP, residues 62–138 USP45) and a
conventional catalytic USP peptidase domain (residue 190–814-end
of protein in USP45) (Ye et al, 2009; Fig 1A).
Here, we demonstrate that USP45 acts to regulate the ubiquityla-
tion of the ERCC1 subunit of the XPF–ERCC1 DNA repair nuclease
that plays a critical role in the repair of DNA interstrand cross-links
(ICL) and in nucleotide excision repair (NER) of UV light-induced
DNA damage (McNeil & Melton, 2012). Consistent with USP45 play-
ing a major role in controlling ERCC1–XPF biology, our data reveal
that knockout of USP45 significantly sensitises cells to ICLs and UV
light, DNA damaging agents that trigger responses controlled by
ERCC1–XPF. We also provide evidence that the ability of ERCC1 to
translocate to foci of DNA damage is controlled by USP45 and show
that ability of cells to repair cyclobutane pyrimidine dimers (CPD),
DNA lesions resulting from UV-C treatment, is greatly impaired in
USP45 knockout cells. Lastly, we observe that endogenous USP45
rapidly and transiently localises to sites of DNA damage induced by
laser irradiation of cells exposed to agents that induce DNA damage
in a manner dependent upon the deubiquitylase activity of USP45,
but independent of its ability to bind ERCC1–XPF. These data high-
light a novel important role for USP45 in controlling ERCC1–XPF
and DNA damage responses.
Results
USP45 associates with the ERCC1–XPF endonuclease
To investigate USP45 function in vivo, we raised antibodies that
detected endogenous USP45 (Supplementary Fig S1). We also
disrupted the USP45 gene in both chronic myelogenous leukaemia
KBM-7 cells (Rago et al, 2007; Supplementary Fig S2A) and in U2OS
osteosarcoma cell line (Supplementary Fig S2B) to knockout USP45
protein expression. To gain clues to USP45 function, we set out to
identify interacting proteins. We used mass spectrometry to
characterise proteins that co-immunoprecipitated with endogenous
USP45 from the wild-type but not from the knockout KBM7 (Fig 1B,
Supplementary Table S1 and Source Data to Fig 1) or U2OS cells
(Fig 1D, Supplementary Table S2 and Source Data to Fig 1). We
observed there were a number of proteins that co-precipitated with
USP45 from wild-type cells but not from the USP45 knockout cell
lines. These included MYH9, MYH10, MYL12B, ZFR and RBMX that
have previously been reported to interact with USP45 in large scale
DUB interaction screens (Sowa et al, 2009).
We decided to focus on proteins that had not been previously
reported to interact with USP45, namely ERCC1, XPF and SLX4.
ERCC1–XPF is a heterodimeric DNA repair endonuclease involved
in the repair of bulky DNA lesions such as UV-induced DNA
damage, and DNA interstrand cross-links (Ciccia et al, 2008; Zhang
& Walter, 2014). Around 50% of ERCC1–XPF in cells binds to SLX4,
a scaffold protein that binds two other DNA repair endonucleases
besides XPF–ERCC1: MUS81-EME1 and SLX1 (Fig 1F) (Fekairi et al,
2009; Munoz et al, 2009; Svendsen et al, 2009; Stoepker et al,
2011a; Saito et al, 2013). The SLX4 complex is not required for
repair of UV-induced DNA damage but is essential for repair of ICLs
(Fekairi et al, 2009; Munoz et al, 2009; Svendsen et al, 2009).
Although ERCC1 forms a heterodimer with XPF (Sijbers et al, 1996;
Ciccia et al, 2008; McNeil & Melton, 2012), XPF was not detected in
KBM7 mass spectrometry analysis of the original USP45 immuno-
precipitates (Fig 1B). However, immunoblotting analysis confirmed
that XPF as well as ERCC1 and SLX4 co-immunoprecipitated with
endogenous USP45 from wild-type, but not USP45 knockout KBM7,
as well as U2OS, cell lines (Fig 1C and E).
USP45 interacts with ERCC1
Previous gel filtration studies have established that the ERCC1–XPF
endonucleases exists in two distinct complexes: one that co-elutes
with SLX4 in high molecular weight fractions and the other which
elutes in lower molecular weight fractions devoid of SLX4 (Munoz
et al, 2009). We next undertook gel filtration of HEK293 cells
extracts, having confirmed that endogenous ERCC1, XPF and SLX4
co-immunoprecipitated with endogenous USP45 in these cells
(Fig 2B). Immunoblot analysis revealed that, like XPF–ERCC1, USP45
eluted in two pools. One pool co-eluted in high molecular weight
fractions with SLX4 complex components (containing XPF, ERCC1,
MUS81 and SLX1) and the other pool co-eluted with XPF and ERCC1
at lower molecular weight fractions (Fig 2A). These data suggested
that USP45 interacts directly with XPF–ERCC1 and not with SLX4.
To define the subunit of XPF–ERCC1 with which USP45 interacts,
we undertook a yeast two-hybrid analysis following the approach
that we previously employed to characterise the interactions of
SLX4 with its nuclease partners (Munoz et al, 2009). This revealed
that USP45 interacted with ERCC1, but not with SLX4 or XPF
(Fig 2C, Supplementary Fig S3). The association of ERCC1 and
USP45 was observed to be markedly more robust than interaction
with other SLX4 components (Fig 2C, Supplementary Fig S3),
further suggesting that USP45 associates with ERCC1.
In agreement with USP45 associating with SLX4 indirectly through
its ability to bind ERCC1, we found that USP45 did not co-immunopre-
cipitate with SLX4 from ERCC1 knockout mouse embryonic fibroblasts
(MEFs) (Fig 2D; McWhir et al, 1993; Melton et al, 1998). Moreover,
we observed that in SLX4 knockout MEFs (Castor et al, 2013),
co-immunoprecipitation of USP45 and ERCC1 was unaffected
(Fig 2E) consistent with USP45 binding to ERCC1 and not to SLX4.
Previous work has revealed that in a fibroblast cell line derived from
a Fanconi anaemia patient deficient in SLX4, the high molecular
weight complex of ERCC1–XPF is absent (Stoepker et al, 2011b). To
verify how loss of SLX4 impacted on USP45 distribution, we under-
took gel filtration analysis of wild-type and SLX4 knockout MEFs.
This revealed that the fraction of USP45 (as well as ERCC1 and XPF)
that co-elutes with SLX4 in the high molecular weight fractions in
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Figure 1. USP45 co-immunoprecipitates with components of the SLX4 complex.
A Schematic representation of the domain architecture of human USP45 protein.
B Endogenous USP45 was immunoprecipitated (IP) from wild-type (WT) and USP45 knockout (KO) KBM7 cells lines. The immunoprecipitates were resolved on a
polyacrylamide gel and stained with Instant Blue. The gel was divided into the indicated sections, and proteins identified by mass spectrometry are detailed in
Supplementary Table S1. The key proteins that we focus on in this study are indicated.
C Endogenous USP45 was immunoprecipitated from the WT and KO KBM7 cell lines and subjected to immunoblotting with the indicated antibodies.
D Endogenous USP45 was immunoprecipitated from WT and USP45 KO U2OS cells lines and analysed as in (B). Mascot scores of the interactors are detailed in
Supplementary Table S2.
E Endogenous USP45 was immunoprecipitated from the WT or KO U2OS cell lines and subjected to immunoblotting with the indicated antibodies. Similar results were
obtained in at least two separate experiments.
F Schematic representation of the SLX4 complex.
Source data are available online for this figure
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extracts derived from wild-type MEFs is lost in SLX4 knockout MEFs
although lower molecular weight is unaffected (Fig 2F).
USP45 interacts specifically with ERCC1–XPF via its
N-terminal 61 residues
Co-immunoprecipitation studies employing fragments of USP45
suggested that the non-catalytic 61 amino acids that lie prior to the
Znf-UBP domain are necessary for binding to ERCC1, as truncation
of these residues abolishes co-immunoprecipitation with endo-
genous ERCC1 (Fig 3A). Consistent with this notion, a fragment of
USP45 encompassing the N-terminal 1–62 residues interacted with
ERCC1 with similar affinity to full-length USP45. The N-terminal
62 residues are highly conserved in all orthologues of USP45 we
have analysed (Fig 3B), but not in other DUBs. We undertook an
alanine scan analysis in which fifteen of the most conserved resi-
dues within the USP45 [1–62] fragment were individually mutated
to Ala, and tested the effect on ERCC1 binding. This revealed that
mutation of three acidic adjacent residues (Asp25, Glu26 or
Asp27) markedly inhibited interaction with ERCC1 without affect-
ing expression of the USP45 [1–62] fragment (Fig 3C, Supplemen-
tary Fig S4). A full-length USP45 [Asp25Ala, Glu26Ala] mutant
failed to co-immunoprecipitate with ERCC1 (Fig 3D). To verify that
the interaction with ERCC1–XPF is specific to USP45, we tested
whether seven different N-terminal Znf-UBP domain-containing
DUBs (USP5, USP16, USP20, USP39, USP44, USP49 and USP51)
associated with endogenous ERCC1–XPF after immunoprecipita-
tion. This revealed that USP45, but not any of the other USP
isoforms tested, associated with ERCC1–XPF (Fig 3E).
USP45 controls ubiquitylation of ERCC1
We reasoned that USP45 might control ubiquitylation of ERCC1,
XPF or SLX4. To address this question, HEK293 cells were treated
with the proteasome inhibitors lactacystin (Fig 4A, left panel) or
bortezomib (Fig 4A, right panel) for different times before lysis in a
buffer containing N-acetylmaleimide to inhibit DUBs dependent on
catalytic cysteine residues, and EDTA to inhibit metalloenzyme
dependent DUBs. As expected, treatment of cells with lactacystin or
bortezomib induced a time-dependent general increase in protein
ubiquitylation (lower panel, Fig 4A). Furthermore, both inhibitors
induced a time-dependent increase in the levels of ERCC1 and
provoked the concomitant appearance of a diffuse higher molecular
weight species of ERCC1, suggestive of ubiquitylation. In contrast,
levels of XPF or SLX4 were not markedly altered, nor was there any
evidence for ubiquitylation of these proteins following inhibition of
the proteasome (Fig 4A).
To further investigate the role of USP45, we compared the levels
of ERCC1, XPF and SLX4 in wild-type and USP45 knockout U2OS
cells (Fig 4B). This revealed that disruption of USP45 in U2OS cells
induced a marked increase in levels of diffuse high molecular
weight species of ERCC1, presumed to be ubiquitylated forms of the
protein, that was accompanied by a decrease in levels of the non-
ubiquitylated species of ERCC1 migrating at 37 kDa. In contrast, the
levels and migration pattern of XPF or SLX4 were unaltered in
USP45 knockout cells (Fig 4B). Restoring expression of wild-type
USP45 in knockout U2OS cells markedly lowered the high molecular
weight species of ERCC1 (Fig 4B).
To explore whether USP45 can directly catalyse deubiquitylation
of ERCC1, we isolated ubiquitylated Flag–ERCC1 (Fig 4C) or GFP–
ERCC1 (Supplementary Fig S5B), expressed in USP45 knockout
U2OS cells treated with lactacystin proteasomal inhibitor. Immuno-
blot analysis with ERCC1 antibody indicated that ERCC1 was signifi-
cantly ubiquitylated under these conditions (Fig 4C, Supplementary
Fig S5B). Treatment of ubiquitylated ERCC1 with wild-type recombi-
nant USP45 induced almost complete deubiquitylation of ERCC1,
judged by a loss in the higher molecular weight species of ERCC1
which is accompanied by an increase in the level of non-ubiquitylated
ERCC1 (Fig 4C). Importantly, the USP45 mutant [Asp25Ala,
Glu26Ala] that displays the same intrinsic catalytic activity as wild-
type USP45 when assayed using a generic ubiquitin–rhodamine
substrate (Supplementary Fig S5A), but that cannot bind ERCC1,
failed to deubiquitylate ERCC1 in parallel experiments (Fig 4C,
Supplementary Fig S5B). As expected, the catalytically inactive
USP45 [Cys199Ala] mutant also failed to deubiquitylate ERCC1
(Fig 4C, Supplementary Fig S5B). Taken together, these data indicate
that disruption of USP45 leads to the accumulation of ubiquitylated
forms of ERCC1, but it appears that the overall levels of ERCC1 are
not affected. Furthermore, USP45 can deubiquitylate ERCC1 in a
manner that requires association of USP45 and ERCC1. In this light,
we observed that 5 other DUBs tested (AMSH, Cezanne, OTUB1,
UCHL1 and USP27X) failed to deubiquitylate ERCC1 under condi-
tions that wild-type USP45 deubiquitylated ERCC1 (Supplementary
Fig S5C). Immunoblot analysis of immunoprecipitated GFP–ERCC1
with chain topology-specific ubiquitin antibodies revealed the pres-
ence of both Lys48- and Lys63-specific chain linkages (Supplemen-
tary Fig S5C). Both the Lys48 and Lys 63 linkages were sensitive to
treatment with wild-type USP45 (Supplementary Fig S5C).
USP45 promotes survival of cells exposed to agents that induce
DNA damage responses controlled by ERCC1–XPF endonuclease
Work from many laboratories has shown that ERCC1 is involved in
the repair of DNA ICLs and for nucleotide excision repair (NER) of
Figure 2. USP45 interacts directly with ERCC1.
A Extracts of HEK293 cells were analysed by gel filtration on a Superdex 200 10/300 GL preparative grade column (GE Healthcare) in buffer containing 0.15 M NaCl,
and every second fraction denatured and analysed by immunoblotting with the indicated antibodies. The white dotted lines indicate that the samples were run on
different polyacrylamide gels.
B Endogenous USP45 or ERCC1 was immunoprecipitated from HEK293 cell lysates and subjected to immunoblotting with the indicated antibodies.
C Yeast two-hybrid (Y2H) assays were performed with a GAL4 DNA-binding domain fusion and/or activation domain for each protein indicated in the table to detect
interaction between these proteins. Cells grown on media lacking LEU, TRP and HIS (to select for bait and prey plasmids) or tested for lacZ reporter gene activity.
D, E Endogenous SLX4 and ERCC1 were immunoprecipitated from extracts of WT or ERCC1 KO MEFs (D), or WT or SLX4 KO MEFs (E) and subjected to immunoblotting
with the indicated antibodies.
F Extracts of WT or SLX4 KO MEFs were analysed by gel filtration as described in (A). Similar results were obtained in at least two separate experiments.
▸
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UV-induced DNA damage (Kaye et al, 1980; Westerveld et al, 1984;
Hoy et al, 1985; Kondo et al, 1989; Busch et al, 1997). The influence
of USP45 on ERCC1 ubiquitylation prompted us to test whether
USP45 is required for ICL repair and NER, using our USP45 knock-
out cells. Before these experiments, we first monitored the growth
rate of wild-type and USP45 knockout U2OS cells and found that the
knockout cells proliferated more slowly, an effect that was rescued
by overexpression of wild-type but not catalytically inactive mutant
(Supplementary Fig S6A). This is reminiscent of cells lacking ERCC1
(Weeda et al, 1997). Flow cytometry analysis indicated, however,
that USP45 knockout did not influence the proportion of cells in G1,
S and G2-M phase in asynchronous cell populations (Supplementary
Fig S6B).
We next performed clonogenic survival assays to compare
the sensitivity of wild-type and USP45 knockout U2OS cells to
mitomycin C (MMC), which induces ICLs, or to UV-C irradiation.
This revealed that compared to the wild-type cells, the USP45 knock-
out U2OS cells were hypersensitive to both MMC (Fig 5A and C)
and UV-C (Fig 5E). Furthermore, expression of wild-type USP45,
but not the USP45 [Asp25Ala, Glu26Ala] mutant or the catalytically
inactive USP45 [Cys199Ala] mutant, rescued the genotoxin hyper-
sensitivity of USP45 knockout U2OS cells (Fig 5A and C). Expres-
sion of similar levels of ectopic wild-type and mutant USP45 in
USP45 knockout cells was confirmed by immunoblot analysis
(Fig 5B and D). The slow growth of USP45 knockout cells (Supple-
mentary Fig S6) raised the possibility that sensitivity to UV and ICLs
was caused by general sickness, but USP45 knockout U2OS cells
were not more sensitive than parental cells to the effects of hydro-
xyurea, a ribonucleotide reductase inhibitor that causes stalling of
replication forks (Yarbro, 1992) (Fig 5F). Taken together, the data
in this section reveal that the catalytic activity of USP45 is required
for repair of ICLs and DNA damage induced by UV light.
Previous work has suggested that ERCC1 deficiency leads to
chromosomal aberrations, including gaps, breaks and radials in
metaphase spreads of MMC-treated Ercc1 null cells (Niedernhofer
et al, 2004b). We therefore explored the levels of chromosome
abnormalities in wild-type and USP45 knockout U2OS cells.
This revealed a significant increase of abnormalities in USP45
knockout cells compared to wild-type cells (Supplementary Fig S7).
To investigate whether USP45 exerts its effects through stabilis-
ing ERCC1 expression, we monitored ERCC1 levels in wild-type and
USP45 knockout cells treated with the protein synthesis inhibitor
cycloheximide. This revealed that exposure of cells to cycloheximide
for 8 h did not markedly affect ERCC1 levels in either the wild-type
or USP45 knockout cells treated in the presence or absence of
MMC (Supplementary Fig S8). Moreover, we observed that overex-
pression of ERCC1 failed to rescue the hypersensitivity of USP45
knockout cells to MMC or UV-C (Supplementary Fig S9). These data
therefore indicate that likely the ubiquitylation of ERCC1, which is
reversed by USP45, controls an aspect of ERCC1 function other than
regulating its stability.
USP45 regulates the recruitment of ERCC1 to the damage
XPF–ERCC1 forms spontaneous foci in cells that probably corre-
spond to telomeres, and we next analysed the impact of USP45 on
spontaneous ERCC1 in U2OS cells by quantifying the proportion of
cell nuclei with 10 or more ERCC1 foci (Stoepker et al, 2011b). This
analysis revealed that USP45 knockout U2OS cells displayed a three
to fourfold reduction in nuclei with 10 or more ERCC1 foci compared
to wild-type cells (Fig 6A and B). Moreover, expression of wild-type
USP45, but not catalytically deficient USP45 [Cys199Ala] mutant in
these cells, restored the number of spontaneous ERCC1 foci almost
to the level seen in wild-type U2OS cells (Fig 6A and B).
Treatment of cells with genotoxins stimulates the formation of
DNA damage-induced XPF–ERCC1 foci. We observed that exposure
of wild-type U2OS cells to MMC (24 h) or UV-C (4 h post-UV) caused
an approximately sevenfold increase in the number of nuclei with 10
or more ERCC1 foci (Fig 6A and B). In contrast, no such increases in
ERCC1 foci were observed in USP45 knockout U2OS cells (Fig 6A
and B). Expression of wild-type USP45, but not the catalytically defi-
cient USP45 [Cys199Ala] mutant in USP45 knockout U2OS cells,
restored the number of DNA damage-induced ERCC1 foci to levels
observed in wild-type cells (Fig 6A and B). Normal DNA damage
responses were initiated in wild-type and USP45 knockout cells as
judged by formation of c-H2AX foci after MMC treatment and XPA
foci after UV-C treatment (Supplementary Figs S10 and S11). Treatment
with the lactacystin proteasomal inhibitor increases ubiquitylation of
ERCC1 (Fig 4A), but had no significant impact on ERCC1 foci forma-
tion in wild-type or USP45 knockout cells (Supplementary Fig S12).
Time-course analysis revealed that in wild-type cells, the number
of ERCC1 containing foci was markedly elevated at 24 and 48 h
post-MMC treatment and declined to near basal levels within 96 h
(Fig 6C, Supplementary Fig S13). In contrast, in USP45 knockout
cells, the number of ERCC1 containing foci remained low at all time
points analysed (Fig 6C, Supplementary Fig S13).
We also explored how USP45 knockout impacts on c-H2AX
foci induced by MMC. After 24 h MMC treatment, the number of
c-H2AX containing foci was high in both wild-type and USP45
knockout cells, indicating that normal DNA damage responses were
Figure 3. The N-terminal 61 residues of USP45 mediate binding to ERCC1.
A HEK293 cells were transiently transfected with the indicated GFP fusion constructs encoding full-length or indicated fragments of USP45. Thirty-six hours post-
transfection cells were lysed and GFP immunoprecipitated. The immunoprecipitates were resolved on a polyacrylamide gel and stained with Instant Blue or
subjected to immunoblotting with the indicated antibodies. GFP empty vector was used as a negative control.
B Sequence alignment of the first 62 residues of USP45 from the indicated species. Conserved residues that were mutated in part (C) are indicated in red. The
residues whose mutation in (C) is shown to inhibit binding to ERCC1 are marked with an asterisk. Residue Thr37 (marked with a solid triangle) was found to
destabilise expression when mutated to Ala.
C, D HEK293 cells were transiently transfected with constructs expressing the indicated wild-type or mutant GFP–USP45 [1–62] fragment (C) or GFP full-length
USP45 (D) or empty GFP (C and D) as a control and processed as described in (A). LICOR–Odyssey quantitation of results shown in (C) is shown in
Supplementary Fig S4.
E As in (C) except HEK293 cells were transfected with the indicated N-terminal Znf-UBP domain-containing DUBs. Similar results were obtained in at least two
separate experiments.
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initiated (Fig 6D, Supplementary Fig S14). Strikingly, however, the
number of c-H2AX foci remained high in USP45 knockout cells even
after 96 h post-MMC treatment under conditions in which the
number of foci had returned to near basal levels with 72 h in
wild-type cells (Fig 6D, Supplementary Fig S14). Similar effects on
c-H2AX foci were reported in Ercc1 knockout MEFs (Niedernhofer
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Figure 4. USP45 deubiquitylates ERCC1.
A HEK293 cells were treated with the proteasome inhibitor lactacystin (5 lM) or bortezomib (10 lM) for the times indicated. Cells were lysed in the presence of 0.1 M
N-ethylmaleimide to inhibit deubiquitylation and lysates were subjected to immunoblotting with indicated antibodies.
B Wild-type (WT) and USP45 knockout (KO) U2OS cells were lysed and subjected to immunoblotting as in (A).
C USP45 KO U2OS cells were transiently transfected with a construct encoding FLAG-ERCC1. Thirty-six hours post-transfection cells were treated with lactacystin
(5 lM) for 6 h and lysed with a buffer containing 0.1 M N-ethylmaleimide. Flag-ERCC1 was immunoprecipitated and treated in the absence or presence of 0.1 lg of
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et al, 2004b), consistent with the defects in USP45 knockout cells
caused by defects in ERCC1 function.
USP45 is recruited to DNA damage sites and controls repair of
UV-induced DNA damage
We next explored whether USP45 localises at sites of DNA damage.
To this end, we used a monoclonal antibody that recognised endog-
enous USP45 in immunofluorescence experiments. USP45 showed a
diffuse staining pattern in both cytoplasmic and nuclear compart-
ments of wild-type U2OS cells. This pattern was specific for USP45
because no signal was observed in USP45 knockout U2OS cells
(Supplementary Fig S1B). Furthermore, the localisation of a GFP-
tagged form of USP45 overexpressed in U2OS cells was similar to
the endogenous protein (Supplementary Fig S1B). We induced DNA
damage in three ways: firstly, cells were incubated with 5-bromo-20-
deoxyuridine and nuclei micro-irradiated along a track in the
nucleus with a 355-nm laser; this treatment induces heterogeneous
range of DNA lesions. In wild-type cells, USP45 formed a stripe
along the track of DNA damage induced in this manner, which also
contained the c-H2AX signal, a well-defined marker of DNA damage
(Fig 7). Secondly, cells were incubated with the intercalating agent
psoralen and nuclei were micro-irradiated along a track using a
355-nm UV-A laser to induce predominantly ICLs (Lachaud et al,
2014). In control experiments, psoralen was replaced by angelicin,
which in the presence of UV-A causes formation of intrastrand
cross-links (a substrate for NER) instead of ICLs. As shown in Fig 7,
in wild-type U2OS cells, USP45 localised to tracks of DNA damage
induced by psoralen/UV-A and by angelicin/UV-A. In each case, the
USP45 stripes contained c-H2AX. In USP45 knockout U2OS cells,
laser stripes contained c-H2AX signal but not USP45 signal (Fig 7).
To investigate whether USP45 is also recruited to DNA damage
induced by UV-C treatment, which has profound disabling effects in
NER-defective cells, U2OS cells were overlaid with microscale
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B Control immunoblot analysis demonstrating that in the USP45 KO U2OS rescue cell lines, similar levels of wild-type and catalytically inactive USP45 [Cys199Ala]
were expressed.
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pore-containing filters and exposed to a UV-C energy source
(254 nm). This revealed recruitment of GFP–USP45, but not GFP
alone, to the regions of localised UV irradiation. These same areas
staining for USP45 co-localised with sites of staining with an anti-
body specific for CPD generated by UV-C irradiation (Fig 8A)
(Gerard et al, 2006; Pathania et al, 2011).
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Figure 6. Defective recruitment of ERCC1 to sites of DNA damage in USP45 knockout cells.
A Wild-type (WT), USP45 knockout (KO) or USP45 KO cells re-expressing wild-type USP45 (RESWT) or catalytically inactive USP45 [Cys199Ala] (RESCA) were used to
analyse ERCC1 foci formation. Staining and analysis of endogenous ERCC1 foci formation was undertaken before (left panel), or after DNA damage induction by
mitomycin C (40 ng/ml, 16 h, middle panel) or UV (20 J/m2 followed by 3-h recovery, right panel). Three independent experiments were performed in which 500 cells
per experiment were analysed. Scale bar, 10 lm.
B Proportion of cells displaying more than 10 endogenous ERCC1 foci were quantified. Three independent experiments were performed in which 500 cells per
experiment were analysed. Results are the mean of 3 experiments  SD.
C The wild-type and USP45 knockout U2OS cells were treated with mitomycin C (40 ng/ml, 16 h) and total number of ERCC1 staining foci per cell was quantified in at
least 50 independent cells at the indicated times. Similar results were obtained in two separate experiments. The data are presented as the average number of ERCC1
staining foci per cell.
D As in (C), except that c-H2AX-staining foci were analysed. The data are presented as the average number of c-H2AX staining foci per cell.
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Given the importance of XPF–ERCC1 in the repair of UV-induced
DNA damage, we next assessed the repair of CPDs in wild-type and
USP45 knockout U2OS cells exposed to UV-C irradiation. To this
end, we used the dot blot method where genomic DNA is probed
with an antibody that recognises CPDs (Patrick, 1977; Schwarz et al,
2002). DNA repair was judged by disappearance of the CPD signal
in dot blot analyses of genomic DNA during recovery from UV
exposure. As shown in Fig 8B, repair of UV-C-induced CPDs in
wild-type cells was observed after 3 h and complete by 24 h. In
contrast in USP45 knockout cells, significant levels of CPD damage
were still observed 24 h after UV-C irradiation (Fig 8B, Supplemen-
tary Fig S15). Similar results were obtained when we carried out
ELISA analysis, instead of dot blot, using a different anti-CPD
antibody (Fig 8C). Taken together, these data indicate that USP45
localises at sites of UV-induced DNA damage, and at intra- and inter-
strand cross-links, and that USP45 is required, like ERCC1 for
efficient NER.
USP45 is recruited transiently to sites of damage independently
of ERCC1–XPF
To study the time course of recruitment of USP45 to sites of laser-
induced DNA damage, we stably expressed GFPNLS–USP45 in U2OS
cells with a nuclear localisation signal (NLS) on the GFP moiety to
ensure nuclear localisation. We induced tracks of DNA damage as
described above and monitored GFP fluorescence at sites of laser-
induced micro-irradiation after BrdU treatment. This experiment
confirmed that GFPNLS–USP45, but not isolated GFPNLS, formed sub-
nuclear stripes along the laser tracks under all conditions employed.
The recruitment of USP45 to these stripes was rapid, occurring
within 30 s and declining thereafter to near basal levels within
5 min (Fig 9). We also observed that in contrast to wild-type USP45,
the catalytically inactive mutant GFPNLS–USP45 [Cys199Ala] when
stably expressed in U2OS cells, was not recruited to laser stripes
(Fig 9). Moreover, GFPNLS–[USP45 residues 62-end] that lacks the
ERCC1-binding motif, was still transiently recruited to laser-induced
sites of DNA damage, whereas the ERCC1-binding GFPNLS–[USP45
residues 1–62] fragment was not recruited to sites of DNA damage
(Supplementary Fig S16A). To confirm that ERCC1 was not required
for recruitment of USP45 to sites of DNA damage, we show that in
ERCC1 knockout MEFs, endogenous USP45 is normally recruited to
sites of damage (Supplementary Fig S16B and C).
Discussion
Little is known about how the activity of DNA repair nucleases is
controlled in cells. Insufficient activity would compromise DNA
repair, whereas excessive activity might result in pathological
genome cleavage events. In this study, we identify USP45 as a regu-
lator of ERCC1 function in cells. Mass spectrometry analysis identi-
fied ERCC1–XPF and the SLX4 scaffold as potentials targets of
USP45 together with a number of other proteins that co-precipitated
with USP45. These included MYH9, MYH10, MYL12B, ZFR and
RBMX that have previously been reported to interact with USP45
(Sowa et al, 2009). There are two pools of ERCC1–XPF in cells—one
is bound to the SLX4 scaffold protein and the other is not (Munoz
et al, 2009; Stoepker et al, 2011b). Gel filtration experiments
showed that USP45 was associated with both pools of XPF–ERCC1.
This observation, together with the findings that USP45 co-
precipitates with XPF–ERCC1 in Slx4 null cells and that ERCC1
interacts with USP45 in a yeast two-hybrid assay, indicate that
USP45 interacts directly with ERCC1.
Our data reveal that the interaction of ERCC1 with USP45 is
specific to this particular DUB as the interaction is mediated by the
N-terminal 62 amino acids that are highly conserved in USP45
orthologues, but are not found in other DUBs. We identify a cluster
of acidic residues (Asp25, Glu26 and Asp27), which lie within a
stretch of seven invariant residues (DEDSSDD, residues 25–31) that
are conserved in all USP45 species we have analysed. This acidic
motif is essential for the interaction as the USP45 [Asp25Ala,
Glu26Ala] mutant fails to bind ERCC1. In future work, it would also
be interesting to explore whether this motif enables USP45 to bind
specifically to ERCC1 or whether it also enables USP45 to interact
with other substrates. Interestingly, all DUBs related to USP45 that
have an N-terminal Znf-UBP domain (USP3, USP5, USP13, USP16,
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Figure 7. USP45 localises at sites of DNA damage.
Representative immunofluorescence images of endogenous wild-type (WT) and
USP45 knockout (KO) U2OS cells treated with no drug, BrdU (10 lM, 24 h),
psoralen or angelicin (25 lM, 3 h). Cells were fixed 10 min after laser micro-
irradiation and stained for localisation of endogenous USP45, phosphorylated
c-H2AX and DAPI. The right-hand panel shows magnification of one micro-
irradiated cell. Similar results were obtained in at least three independent
experiments. Scale bar, 10 lm.
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USP20, USP22, USP33, USP39, USP44, USP49 and USP51) also
possess distinct N-terminal residues that are highly conserved
between species but not between USP isoforms. By analogy with
USP45, it would be interesting to explore whether these N-terminal
motifs also operate to direct interactions of Znf-UBP domain-
containing DUBs with their target(s).
Previous work has revealed that several components of the DNA
damage repair pathways are controlled by deubiquitylation. These
include the deubiquitylation of PCNA and FANCD2 (Garcia-Higuera
et al, 2001) catalysed by USP1 (Nijman et al, 2005), deubiquityla-
tion and stabilisation of 53BP1 or claspin by USP28 (Zhang et al,
2006) and more recently is has been reported that USP3 catalyses
the deubiquitylation of H2AX and c-H2AX (Sharma et al, 2014).
Thus far, there have not been any reports regarding the regulation
of ERCC1–XPF by ubiquitylation, but our results indicate that USP45
counteracts ubiquitylation of ERCC1. Supporting this conclusion is
the finding that ubiquitylated forms of ERCC1 accumulate in cells
lacking USP45, accompanied by a concomitant decrease in the levels
of the non-ubiquitylated form of ERCC1. We also observe that in
vitro wild-type USP45 can catalyse the deubiquitylation of ERCC1
that has been immunoprecipitated from cells treated with the
proteasome inhibitor lactacystin (Fig 4C, Supplementary Fig S5B).
Importantly, we find that the USP45 mutant [Asp25Ala, Glu26Ala]
that is catalytically active but that cannot bind to ERCC1 (Supple-
mentary Fig S5A) failed to deubiquitylate ERCC1 in vitro, indicating
that specific interaction between ERCC1 and USP45 is essential to
trigger deubiquitylation. Therefore, a function of USP45 appears to
control ubiquitylation of ERCC1.
Cells lacking USP45 are hypersensitive to the same spectrum of
genotoxic agents—UV-C and ICL-induced DNA damage—as cells
lacking XPF or ERCC1. Like cells defective in XPF or ERCC1,
USP45 knockout cells show defects in the repair of UV-induced
CPD photoproducts (Fig 8B and C, Supplementary Fig S15) and
defects in the resolution of H2AX foci during recovery from
exposure to ICLs (Fig 6D, Supplementary Fig S14). Furthermore,
XPF–ERCC1 is the only known protein common to both NER and
ICL repair (Niedernhofer et al, 2004a; Muniandy et al, 2009; Orelli
et al, 2010; Wang et al, 2011). On this basis, we speculate that is
likely that XPF–ERCC1 is the major target of USP45 in controlling
DNA repair. Consistent with this notion, the DNA damage sensi-
tivity of USP45 knockout cells is only rescued by wild-type USP45
and not by an active USP45 [Asp25Ala, Glu26Ala] mutant that is
unable to bind ERCC1 (Fig 5C) or catalytically inactive USP45
[Cys199Ala] (Fig 5A). This implies that the rescue of the sensitiv-
ity phenotype depends on the interaction between ERCC1 and
USP45 as well as its catalytic activity. We cannot exclude the
possibility that there may be other substrates of USP45 relevant
to genome stability, but our data strongly suggest therefore
that ERCC1 is the major substrate of USP45 in promoting DNA
repair.
How does ERCC1 deubiquitylation promote DNA repair? Our find-
ings that overexpression of ERCC1 did not rescue the sensitivity of
USP45 knockout cells to MMC and UV-C (Supplementary Fig S9) and
that USP45 knockout does not affect ERCC1 half-life (Supplementary
Fig S8), suggest that the role of USP45 in controlling ERCC1 ubiquity-
lation goes beyond control of ERCC1 stability and expression levels.
Instead ubiquitylation/deubiquitylation appears to control ERCC1
function in a more direct way. In this light, USP45-defective cells also
show a striking reduction in the DNA damage-induced formation of
ERCC1 foci, which was not rescued by proteasome inhibition (Supple-
mentary Fig S12). This defect in ERCC1 recruitment could in principle
account for the DNA repair defects of USP45-defective cells. Thus, the
major role of ERCC1 deubiquitylation by USP45 may be to enable
ERCC1–XPF to gain access to DNA damage sites. How removal of
ubiquitin from ERCC1 impacts on its recruitment to sites of DNA
damage at the molecular level will be an interesting avenue for future
investigation. It will also be a challenging endeavour because the
mechanism of recruitment of ERCC1–XPF to ICLs differs from recruit-
ment to UV-induced damage (JR, unpublished data; Volker et al,
2001). It will also be fascinating to identify the E3 ligase responsible
for ERCC1 ubiquitylation and work out how it is regulated.
We showed that USP45 is also recruited to sites of DNA damage
lesions, in a manner that is dependent on functional catalytic activ-
ity of the deubiquitylase domain, but independent of its ability to
bind ERCC1 (Fig 9, Supplementary Fig S16). These results suggest
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Figure 9. USP45 recruitment to sites of DNA damage is rapid and
transient.
Live-cell fluorescence analysis of U2OS cells stably expressing either GFPNLS
empty, wild-type (WT) USP45 or catalytically inactive USP45 [Cys199Ala]. Cells
were treated with BrdU (10 lM, 24 h), psoralen or angelicin (25 lM, 3 h) and
images captured at the indicated times after laser micro-irradiation. The location
of the micro-irradiation stripe in each cell is indicated with a yellow line. Similar
results were obtained in at least two independent experiments. Scale bar, 10 lm.
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that there are additional component(s) to be identified that recruit
USP45 to sites of DNA damage. In future work, it would be
important to elucidate the mechanism by which USP45 is recruited
to sites and define whether there are new USP45 substrates located
in the vicinity of DNA lesions. It is interesting to note that a recent
paper describing a complementary set of functional screens to iden-
tify DUBs involved in DNA damage responses did not identify
USP45 (Nishi et al, 2014). One of the screening approaches
employed by these authors involved analysing the ability of tran-
siently expressed GFP-tagged DUBs to form stripes at sites of micro-
irradiation. However, the authors found that GFP–USP45 is localised
mostly in the cytoplasm after transient transfection. This is also
consistent with our transient transfection data (not shown).
However, we have found that endogenous USP45 is localised in
cytoplasm and nucleus (Supplementary Fig S1B) and is robustly
recruited to DNA damage stripes (Fig 7). In addition, the GFP–
USP45 construct we have employed, that is recruited to sites of
DNA damage, possesses a nuclear localisation signal in the GFP
motif to promote nuclear expression of overexpressed GFP–USP45.
We also generated cells that stably express much lower levels of
GFP–USP45 than observed under transient transfection conditions,
and this might also facilitate the visualisation of USP45 binding to
DNA damage sites (Fig 9).
Several studies have found ERCC1 to be overexpressed in
cisplatin-resistant tumours, and the levels of ERCC1 mRNA and
protein have been used to profile tumours to predict responses to
platinum compounds (Ciccia et al, 2008; Kirschner & Melton, 2010;
McNeil & Melton, 2012). It would be interesting to explore whether
there were any mutations that disrupted USP45 in these tumours or
other tumours. Indeed, as mentioned in the introduction, cancer
genome analysis has revealed that ~12% of prostate cancers, ~5%
of diffuse large B-cell lymphoma and a number of other tumours
display deletions in the USP45 gene (http://www.cbioportal.org).
Whilst cisplatin may not be widely used in the therapy of these
tumours, as personalisation of medicine moves forward, it would be
worth exploring whether patients displaying loss of function muta-
tions in USP45 would be sensitised to platinum therapy. Moreover,
it would be interesting to screen unclassified Fanconi anaemia
patients, where no gene has been assigned, for mutations in USP45.
It would also be of interest to explore whether inhibiting USP45
could be employed as a therapeutic strategy to induce sensitisation
of cancer cells to platinum-based therapies.
Materials and Methods
Reagents
Ubiquitin monomer, BSA, Tris, Triton X-100 and DTT, trimethyl-
psoralen (TMP), hydroxyurea, angelicin and BrdU were purchased
from Sigma-Aldrich. Di-ubiquitin topoisomers (linear, K6-, K11-,
K27-, K29-, K33-, K48- and K63-linked ubiquitin–ubiquitin) were
purchased from Boston Biochem. Complete protease inhibitors cock-
tail tablets were obtained from Roche. Tween-20, Colloidal blue
staining kit and precast SDS–polyacrylamide Bis-Tris gels (Invitro-
gen). MMC was from Duchefa.
All recombinant proteins, plasmids and antibodies generated for
the present study are available upon request and described in
further detail on our reagents website (https://mrcppureagents.
dundee.ac.uk/).
Antibodies
The following antibodies were raised by the Division of Signal
Transduction Therapy (DSTT) at the University of Dundee in sheep
and affinity-purified against the indicated antigens: anti-USP45 (1st,
2nd and 3rd bleed of S052D, residues 756–780 of human USP45) and
(1st, 2nd and 3rd bleed of S109D, residues 29–80 of human USP45),
ERCC1 (3rd bleed of S185D, residues 1–200 of human ERCC1), mouse
ERCC1 (3rd bleed of S161D, residues 1–200 of mouse ERCC1), SLX4
(3rd bleed of S714C, residues 1,535–1,834 of human SLX4), mouse
SLX4 (3rd bleed of S819C, residues 166–end of mouse SLX4), mouse
XPF (3rd bleed of S164D, residues 1–200 of mouse XPF), SLX1 (3rd
bleed of S701B, residues 100–275 human SLX1). Human Mus81 was
from Immunoquest. Total FK2 ubiquitin antibody and K48-linkage-
specific ubiquitin antibodies (clone Apu2) was from Millipore.
GAPDH, rabbit anti-c-H2AX and K63-linkage-specific ubiquitin
antibodies (D7A11) were from Cell Signalling. Secondary antibodies
coupled to horseradish peroxidase and human XPF (clone219) were
from Thermo Scientific. USP45 for immunofluorescence was from
Sigma-Aldrich (H1A029602). Anti-Thymine Dimer mAb (CPD), clone
KTM53, was from Kamiya Biomedical Company.
General methods
Restriction enzyme digestions, DNA ligations and other recombinant
DNA procedures were performed using standard protocols. All
mutagenesis was performed using the QuikChange site-directed
mutagenesis method (Stratagene) with KOD polymerase (Novagen).
All DNA constructs were verified by DNA sequencing, which was
performed by The Sequencing Service, School of Life Sciences,
University of Dundee, using DYEnamic ET terminator chemistry
(Amersham Biosciences) on Applied Biosystems automated DNA
sequencers. DNA for mammalian cell transfection was amplified in
E. coli DH5a strain, and plasmid preparation was done using Qiagen
Maxi prep Kit according to manufacturer’s protocol.
Buffers
Lysis buffer for mammalian cell lysis contained 50 mM Tris–HCl
(pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% (w/v)
Triton, 1 mM sodium orthovanadate, 10 mM sodium glycerophos-
phate, 50 mM sodium fluoride, 10 mM sodium pyrophosphate,
0.27 M sucrose, 0.1% (v/v) 2-mercaptoethanol, 1 mM benzamidine
and 0.1 mM PMSF. Buffer A contained 50 mM Tris–HCl (pH 7.5)
and 0.1 mM EGTA. TBS-Tween (TTBS) was Tris–HCl (pH 7.5),
0.15 M NaCl and 0.2% (v/v) Tween-20.
Cell culture and transfections
HEK293 and U2OS cells were cultured on 10-cm dishes in
DMEM supplemented with 10% (v/v) foetal bovine serum, 2 mM
L-glutamine, 100 U/ml penicillin and 0.1 mg/ml streptomycin. For
transfection, each dish of adherent cells was transfected with
5–10 lg of plasmid DNA and 20 ll of 1 mg/ml polyethylenimine
(Polysciences) as described previously (Durocher et al, 2002). The
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cells were cultured for a further 36 h and lysed in 0.3 ml ice-cold
lysis buffer per dish, lysates were clarified by centrifugation at 4°C
for 15 min at 16,200 g, and the supernatants were frozen in aliquots
in liquid nitrogen.
Immunoprecipitation
For immunoprecipitation of GFP, TRAP-GFP beads were used.
0.5–5 mg of lysates was incubated with 10–20 ll of antibody–resin
conjugate for 2 h at 4°C under gentle agitation, and the immunopre-
cipitates were washed three times with lysis buffer containing
0.15 M NaCl and then twice with buffer A. Proteins were eluted by
resuspending washed immunoprecipitates in 30 ll of 1× SDS sample
buffer.
Immunoblotting
Cell lysates (20 lg), purified proteins or immunoprecipitates in SDS
sample buffer were subjected to electrophoresis on a polyacrylamide
gel and transferred to nitrocellulose membranes. The membranes
were incubated for 1 h with TTBS containing 5% (w/v) skimmed
dried milk powder. The membranes were immunoblotted in the same
buffer 16 h at 4°C with the indicated primary antibodies. Sheep anti-
bodies were used at a concentration of 1 lg/ml, whereas commercial
antibodies were diluted 1,000- to 5,000-fold. The blots were then
washed with TTBS and incubated for 1 h at room temperature with
secondary HRP-conjugated antibodies diluted 2,500-fold in 5% (w/v)
skimmed milk in TTBS. After repeated washes, the signal was
detected with the enhanced chemiluminescence reagent and the X-ray
films were processed in a Konica Minolta Medical SRX-101 film
processor.
Gel filtration
For gel filtration experiments, cell extracts (2 ml containing 5 mg
protein) were filtered through a 0.22-lm filter and loaded on a
Superdex 200 10/300 GL preparative grade column (GE Healthcare)
in 50 mM Tris–HCl 7.4 buffer containing 1 mM EDTA, 0.15 M
sodium chloride and 0.1% (v/v) 2-mercaptoethanol. The flow rate
was 1.0 ml/min, and fractions of 1 ml (200) were collected. Molecu-
lar weight markers (Bio-Rad) were as follows: Dextran blue
(2,000 kDa), thyroglobulin (670 kDa) and bovine gamma globulin
(158 kDa). Every second fraction was denatured and subjected to
Western blot analysis.
Expression of DUB enzymes
For bacterial protein expression, cultures were initially grow at 37°C
until OD600 was between 0.4 and 0.6, then the temperature was
reduced to 15°C and cultures were induced with 400 lM isopropyl
b-D-1-thiogalactopyranoside and grown for further 16–18 h. Cultures
were harvested, lysed and affinity purified on glutathione–
Sepharose. The purified GST-USP45 was then further purified by ion
exchange chromatography on a HiTrap SP-Sepharose column at pH
7.5 with a linear gradient between 0 and 500 mM NaCl. The frac-
tions containing USP45 were pooled and dialysed into 50 mM Tris–
HCl pH 7.5, 270 mM sucrose, 0.1 mM EGTA, 0.03% (V/V) Brij-35
and 0.1% (v/v) 2-mercaptoethanol.
Rhodamine DUB assay
Experiments were performed using rhodamine 110-glycine and
20 ng/ll of each DUB at 30°C during time indicated in each figure in
40 mM Tris–HCl buffer at pH 7.6, with 5 mM DTT and 0.05 mg/ml
BSA. Samples were prepared in triplicates and 215 analysed in
96-well plates using a Perkin Elmer Envision 2104 multi-label reader
at Excitation/Emission 485/535 nm.
In vitro DUB assays
DUB in vitro activity was performed using 100 ng of each DUB. Both
enzymes and substrates were freshly mixed in reaction buffer
(40 mM Tris–HCl, pH 7.6, 5 mM DTT, 0.005% (w/v) BSA for each
run. The reaction mixture was incubated at 30°C for 60 min. The
reaction was stopped by adding the SDS loading buffer if the sample
was used to run a 8–10% (w/v) bis-acrylamide gel.
Identification of USP45 interacting protein by mass spectrometry
Fifty milligram of cell lysates was pre-cleared by incubation with
50 ll of protein G-Sepharose 1 h at 4°C, filtration and by incubation
with 100 ll of pre-immune IgG covalently coupled to protein
G-Sepharose for 1 h at 4°C on a rolling shaker. The supernatants
were then incubated with 50 lg of anti-USP45-specific antibody
covalently coupled to protein G-Sepharose for 1 h at 4°C on a rolling
shaker. The immunoprecipitates were washed three times with
10 ml of lysis buffer containing 0.2 M NaCl and twice with 10 ml of
buffer A. The beads were resuspended in a total volume of 30 ll of
LDS sample buffer (Invitrogen). The samples were then filtered with
a 0.44-lm Spin-X filter (Corning), reduced with 10 mM dithiothreitol
and alkylated with 50 mM iodoacetamide in 0.1 M NH4HCO3
(30 min at room temperature), boiled and subjected to electro-
phoresis on a NuPAGE Bis-Tris 4–12% (w/v) polyacrylamide gel.
Colloidal Coomassie stained gel was divided into pieces, each of
which were washed with 0.1 M NH4HCO3 and 50% (v/v) acetoni-
trile/50 mM NH4HCO3, dried and incubated with 25 mM triethylam-
monium bicarbonate with 5 lg/ml trypsin 16 h at 30°C on shaker.
The resultant peptides were submitted to LC-MS on a Proxeon
EASY-nLC nano-liquid chromatography system coupled to a
Thermo-LTQ-Orbitrap mass spectrometer. Data files were searched
against the SwissProt human database using Mascot (http://www.
matrixscience.com) run on an in-house system, with 10 p.p.m. mass
accuracy for precursor ions, a 0.8-Da tolerance for fragment ions,
and allowing for carbamidomethyl (C) as fixed modification and for
oxidation (M) as variable modification. Peptide mass fingerprinting
data analysis was performed using OLMAT (http://www.proteinguru.
com/MassSpec/OLMAT).
Laser irradiation and confocal microscopy
U2OS cells were seeded in 35-mm glass bottom dishes at 1 × 106
cells per dish and incubated with psoralen TMP, angelicin (both at
25 lM) for at least 2 h or with BrdU at 10 lM for 24 h (Sigma-
Aldrich). Cells were kept in the dark from this point on. A PALM
MicroBeam system (Zeiss Microimaging) was employed in this
study. We used the 355-nm UV laser through a Plan Fluor 40X/1.25d
n.a. oil at 20 and 25% energy for TMP/angelicin and BrdU,
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respectively, to irradiate a 3 × 20 pixel region internal to the nuclei
of the cells. Cells were then subjected to indirect immunofluores-
cence as describe previously (Davis et al, 2012). Each experiment
was done a minimum of three times, and a minimum of 100 cells
was PUV-A laser-irradiated per replicate.
Yeast two-hybrid assay
Yeast strain AH109 (Invitrogen) has a HIS3 gene and a lacZ gene
regulated by Gal4-binding sites. This strain was transformed with a
pAS2.6 plasmid (Invitrogen) encoding USP45 fused to the DNA-
binding domain of Gal4 (the plasmid also has the TRP1 selectable
marker) and with pACT2.6 plasmids (Invitrogen) encoding XPF
and ERCC1 to the Gal4 activation domain. The reverse experiment
using USP45 fused to the Gal4 activation domain (these plasmids
had the LEU2 selectable marker) and ERCC1 and SLX4 fused to the
DNA-binding domain of Gal4. Empty vectors were used as control
as well as USP27X (a DUB another member of the USP family).
Cells were plated onto minimal medium lacking leucine (LEU) and
tryptophan (TRP) and onto synthetic complete media laking LEU
and TRP and histidine (HIS) to assay reporter gene activation. Cells
from the LEU TRP plate were overlaid with a nitrocellulose
filter that was frozen in liquid nitrogen. The filter was then placed
on a piece of filter paper impregnated with X-Gal (5-bromo-4-
chloro-3-indolyl-b-D-galactopyranoside) to test for lacZ expression
that resulted in a blue colour.
Induction of DNA damage and clonogenic cell survival assays
For the cytotoxicity assays, 500 cells were plated in six replicates
onto 6-well plates in complete growth medium. After cells
attached, they were treated with indicated concentration of MMC
for 24 h before medium was replaced with fresh growth medium
or with the indicated dose of UV using a Spectrolinker XL-1500 UV
cross-linker. The number of colonies with > 100 cells was counted.
For each genotype, cell viability of untreated cells was defined as
100%. Data are represented as mean  SEM from three indepen-
dent experiments. In FOCI analysis, at least 100 cells of three inde-
pendent experiments were analysed using ImageJ with plugin
PzFOCI.
Analysis of chromosomal aberrations
U2OS cells were initially plated in DMEM containing 10% FBS
until cells reached 60–70% confluence. Cell cultures were treated
with MMC at a final concentration of 100 ng/ml and diepoxy
butane (DEB) at a final concentration of 0.1 lg/ml for 48 h. All
cultures were harvested following conventional cytogenetic protocol
(Brown & Lawce, 1997). Briefly, the cell cultures were treated with
0.1 lg/ml Colcemid (Irvine Scientific) approximately 30 min before
the initiation of harvest. For chromosome preparations, the cells
were harvested following conventional cytogenetic protocol of
hypotonic treatment (75 mM KCl) and freshly prepared chilled 3:1
acetone:methanol fixation. This was followed by four additional
fixation cycles and air-dried slide preparation. The slides were
‘aged’ in a hot oven at 60°C over 16 h, followed by Giemsa stain-
ing (Invitrogen). A total of 25 metaphases were scored for each
culture.
Analysis of cell cycle by flow cytometry
U2OS and KBM7 cells were analysed for their respective cell cycle
phase distribution using flow cytometry. Cells were trypsinised in
the case of U2OS, washed with PBS + 0.2% (w/v) BSA and resus-
pended in flow cytometry tubes. Cells were then fixed by 70% (v/v)
ice-cold ethanol and stored at 20°C until analysis. After washing
fixed cells once with PBS, RNase A (50 lg/ml) and PI (50 lg/ml)
were added to the cells and incubated in the dark at room tempera-
ture (25°C) for 20 min. The live cell populations were then subjected
to quantitative measurement of DNA content by flow cytometry
using a FACSCantoTM (BD Biosciences) and cell cycle distribution
and the percentage of G2–S–G1 cells determined by the Watson
(pragmatic) modelling algorithm using FlowJo software (Treestar).
UV-C CPD analysis
Cells grown on glass plates (VWR) were either fixed directly with
4% (v/v) paraformaldehyde and permeabilised with 0.2% Triton
X-100 in PBS, or pre-extracted before fixation with 0.5% (v/v)
Triton X-100 in CSK buffer (cytoskeletal buffer: 10 mM PIPES
pH 7.0, 100 mM NaCl, 300 mM sucrose, 3 mM MgCl2). For CPD
staining, DNA was denatured with 0.5 M NaOH for 5 min. Samples
were blocked in 5% (w/v) BSA (bovine serum albumin; Sigma-
Aldrich) in PBS supplemented with 0.1% (v/v) Tween before
incubation with primary and secondary antibodies conjugated to
Alexa-Fluor 488 or 594 (Invitrogen) (Adam et al, 2013). The
samples were analysed in a confocal Leica Microscope 510.
Southern dot blot analysis
Cells were treated with UV (20 J/m2), and genomic DNA was
extracted at indicated time points using the Qiagen DNeasy blood
and tissue extraction kit, as per manufacturer’s instructions. Five
nanogram of genomic DNA was diluted to 100 ll with 0.5 M of
NaOH and 1.5 M of NaCl, and samples were boiled at 95°C to dena-
ture the DNA and blotted on a nylon membrane followed by UV
cross-linking (DNA containing side facing downwards) to fix DNA
onto the membrane. The blot was blocked with 5% (w/v) milk
TBST for 1 h at room temperature and incubated with anti-thymi-
dine mouse monoclonal antibody (against CPDs) (Kamiya, USA)
overnight and detected with anti-mouse IgG horseradish peroxidase-
labelled secondary antibody, similar to Western blotting procedures.
Control of total cDNA was measured with Abcam dsDNA antibody
(ab27156).
CPD ELISA kit
High Sensitivity CPD/Cyclobutane Pyrimidine Dimer Elisa kit
(NM-MA-K001) was from Cosmo Bio. Cells were treated with UV
(20 J/m2), and genomic DNA was extracted at indicated time points
using the Qiagen DNeasy blood and tissue extraction kit, as per
manufacturer’s instructions. 0.4 lg/ml of genomic DNA was diluted
with 1× assay diluent, heated at 100°C for 10 min. After samples
were chill rapidly in an ice for 15 min, 50 ll of each samples was
added to each well of the ELISA plate wells pre-coated with protamine
sulphate and dry completely during 18 h at 37°C. For the DNA
damage detection, the manufacturer protocol was followed. Calf
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thymus DNA, UV-C irradiated (10 J/m2) and not irradiated was
used as positive and negative samples, respectively.
Cell growth assays
Cells (2,000–3,000 per well) WT/K0 USP45 or rescue experiment
with WT or Cys199Ala mutant were seeded into the inner of
96-well plates in eight replicates and allowed to attach for 16 h in
the case of U2OS cells. Cell viability was determined using CellTiter
96 AQueous One Solution Cell Proliferation Assay (MTS) according
to the manufacturer’s instructions. Results were plotted with a
best-fit sigmoidal variable slope dose–response curve, and GI50
(growth inhibition by 50%) values were calculated using GraphPad
Prism 5.0. The MTS assay was then performed 24, 48, 72, 96 and
120 h post-seeding. Results are presented as the fold change in
absorbance over the 5-day period relative to the assay start point (24 h
post-seeding or day 0). The cells were assayed in eight replicates.
Supplementary information for this article is available online:
http://emboj.embopress.org
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